76 related articles for article (PubMed ID: 2448626)
1. Preparation of [3H]-oxymorphazone and its binding to rat brain membranes.
Borsodi A; Varga E; Toth G; Hosztafi S
NIDA Res Monogr; 1986; 75():220-3. PubMed ID: 2448626
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and binding of 3H-oxymorphazone to rat brain membranes.
Varga E; Toth G; Benyhe S; Hosztafi S; Borsodi A
Life Sci; 1987 Apr; 40(16):1579-88. PubMed ID: 2436019
[TBL] [Abstract][Full Text] [Related]
3. Effects of oxymorphazone in frogs: long lasting antinociception in vivo, and apparently irreversible binding in vitro.
Benyhe S; Hoffmann G; Varga E; Hosztafi S; Toth G; Borsodi A; Wollemann M
Life Sci; 1989; 44(24):1847-57. PubMed ID: 2472540
[TBL] [Abstract][Full Text] [Related]
4. Irreversible opiate agonists and antagonists: the 14-hydroxydihydromorphinone azines.
Hahn EF; Carroll-Buatti M; Pasternak GW
J Neurosci; 1982 May; 2(5):572-6. PubMed ID: 6176696
[TBL] [Abstract][Full Text] [Related]
5. A quantitative study of [3H]D-Ala2-D-Leu5-enkephalin binding to rat brain membranes. Evidence that oxymorphone is a noncompetitive inhibitor of the lower affinity delta-binding site.
Rothman RB; Bowen WD; Herkenham M; Jacobson AE; Rice KC; Pert CB
Mol Pharmacol; 1985 Mar; 27(3):399-409. PubMed ID: 2579319
[TBL] [Abstract][Full Text] [Related]
6. Irreversible opiate agonists and antagonists. II. Evidence against a bivalent mechanism of action for opiate azines and diacylhydrazones.
Hahn EF; Nishimura S; Goodman RR; Pasternak GW
J Pharmacol Exp Ther; 1985 Dec; 235(3):839-45. PubMed ID: 2416909
[TBL] [Abstract][Full Text] [Related]
7. Receptor binding and analgesic properties of oxymorphazone.
Galetta S; Ling GS; Wolfin L; Pasternak GW
Life Sci; 1982 Sep 20-27; 31(12-13):1389-92. PubMed ID: 6183551
[TBL] [Abstract][Full Text] [Related]
8. Oxymorphazone: a long-acting opiate analgesic.
Ling GS; Galetta S; Pasternak GW
Cell Mol Neurobiol; 1984 Mar; 4(1):1-13. PubMed ID: 6204757
[TBL] [Abstract][Full Text] [Related]
9. Tritiated-6-beta-fluoro-6-desoxy-oxymorphone: a highly selective ligand for the opiate mu receptor whose binding is characterized by low nonspecific binding.
Rothman RB; Danks JA; Jacobson AE; Burke TR; Rice KC; Pert CB
Neuropeptides; 1984 Jun; 4(4):311-7. PubMed ID: 6206435
[TBL] [Abstract][Full Text] [Related]
10. Long-acting opiate agonists and antagonists: 14-hydroxydihydromorphinone hydrazones.
Pasternak GW; Hahn EF
J Med Chem; 1980 Jun; 23(6):674-6. PubMed ID: 6156240
[TBL] [Abstract][Full Text] [Related]
11. Irreversible opiate agonists and antagonists. IV. Analgesic actions of 14-hydroxydihydromorphinone hydrazones.
Williams CL; Bodnar RJ; Clark JE; Hahn EF; Burks TF; Pasternak GW
J Pharmacol Exp Ther; 1988 Apr; 245(1):8-12. PubMed ID: 2452249
[TBL] [Abstract][Full Text] [Related]
12. Differentiating aspects of opioid receptor binding by [3H](-) (1R,5R,9R,2''S)-5,9-dimethyl-2-tetrahydrofurfuryl-2'-hydroxy-6,7- benzomorphan hydrochloride ([3H]Mr 2034), a drug preferentially acting on kappa-receptors.
Ensinger HA
Arzneimittelforschung; 1985; 35(1A):447-51. PubMed ID: 2985096
[TBL] [Abstract][Full Text] [Related]
13. Reversible and irreversible binding of beta-funaltrexamine to mu, delta and kappa opioid receptors in guinea pig brain membranes.
Tam SW; Liu-Chen LY
J Pharmacol Exp Ther; 1986 Nov; 239(2):351-7. PubMed ID: 3021954
[TBL] [Abstract][Full Text] [Related]
14. Solubilization and preliminary characterization of mu and kappa opiate receptor subtypes from rat brain.
Chow T; Zukin RS
Mol Pharmacol; 1983 Sep; 24(2):203-12. PubMed ID: 6310362
[TBL] [Abstract][Full Text] [Related]
15. Irreversible opiate agonists and antagonists. III. Phenylhydrazone derivatives of naloxone and oxymorphone.
Hahn EF; Itzhak Y; Nishimura S; Johnson N; Pasternak GW
J Pharmacol Exp Ther; 1985 Dec; 235(3):846-50. PubMed ID: 2416910
[TBL] [Abstract][Full Text] [Related]
16. Binding properties of the pure opioid antagonist [3H](N-propyl)-noroxymorphone in rat brain membranes.
Tóth G; Benyhe S; Hosztafi S; Borsodi A
Neurobiology (Bp); 1993; 1(4):327-35. PubMed ID: 8069290
[TBL] [Abstract][Full Text] [Related]
17. Naloxonazine effects on the interaction of enkephalin analogs with mu-1, mu and delta opioid binding sites in rat brain membranes.
Cruciani RA; Lutz RA; Munson PJ; Rodbard D
J Pharmacol Exp Ther; 1987 Jul; 242(1):15-20. PubMed ID: 3039108
[TBL] [Abstract][Full Text] [Related]
18. Antagonist-induced opioid receptor up-regulation. II. Regionally specific modulation of mu, delta and kappa binding sites in rat brain revealed by quantitative autoradiography.
Morris BJ; Millan MJ; Herz A
J Pharmacol Exp Ther; 1988 Nov; 247(2):729-36. PubMed ID: 2846828
[TBL] [Abstract][Full Text] [Related]
19. [3H]-[H-D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2] ([3H]CTOP), a potent and highly selective peptide for mu opioid receptors in rat brain.
Hawkins KN; Knapp RJ; Lui GK; Gulya K; Kazmierski W; Wan YP; Pelton JT; Hruby VJ; Yamamura HI
J Pharmacol Exp Ther; 1989 Jan; 248(1):73-80. PubMed ID: 2563293
[TBL] [Abstract][Full Text] [Related]
20. [Stability of opiate receptors of wet and lyophilized preparations of rat brain membranes].
Zaĭtsev SV; Kurochkin IN; Sergeeva MG; Varfolomeev SD
Biokhimiia; 1984 Jul; 49(7):1127-33. PubMed ID: 6089917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
